logo
SVA_building
COVID-19 Vaccine – CoronaVac ®, the inactivated COVID-19 vaccine developed by SINOVAC, has been approved for use in more than 60 countries and regions worldwide. At this time, over 2.9 billion doses of CoronaVac ® have been delivered globally, making SINOVAC the largest China-based COVID-19 vaccine provider the international market

SINOVAC Reports Unaudited First Half of 2022 Financial Results

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June 30, 2022

By AP News
Published - Dec 29, 2022, 08:33 AM ET
Last Updated - Aug 05, 2024, 06:24 AM EDT

BEIJING, China,--(BUSINESS WIRE)--Dec 29, 2022--

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June 30, 2022.

First Half of 2022 Financial Summary

Article Source
Quick Links
Categories
Our Offices
  • 10kInfo, Inc.
    13555 SE 36th St
    Bellevue, WA 98006
  • 10kInfo Data Solutions, Pvt Ltd.
    Claywork Create
    11 km, Arakere Bannerghatta Rd, Omkar Nagar, Arekere,
    Bengaluru, Karnataka 560076
4.2 12182024